Testing effectiveness (Phase 2)Active Not RecruitingNCT06524375
What this trial is testing
Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period
Who this might be right for
Chronic Lymphocytic Leukemia
Genentech, Inc. 118